LTLu Tian

Lu Tian

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Lu Tian has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Bojian Fei

    Department of Gastrointestinal Surgery, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu 214122, China

    1 shared publication
  • Chaoqun Li

    Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu 214062, China; Laboratory of Cancer Epigenetics, Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu 214122, China

    1 shared publication
  • Chu Hao

    Laboratory of Cancer Epigenetics, Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu 214122, China

    1 shared publication
  • Haocheng He

    College of Synthetic Biology Industry, Center for Cell and Gene Therapy Research, Hunan University of Arts and Science, Changde, China

    1 shared publication
  • He Li

    Shenzhen Key Laboratory of Genome Manipulation and Biosynthesis, Key Laboratory of Quantitative Synthetic Biology, Shenzhen Institute of Synthetic Biology, Shenzhen Institutes of Advanced Technology, Chinese Academy of Sciences, Shenzhen, China

    1 shared publication
  • Jing Zhao

    Wuxi Cancer Institute, Affiliated Hospital of Jiangnan University, Wuxi, Jiangsu 214062, China; Laboratory of Cancer Epigenetics, Wuxi School of Medicine, Jiangnan University, Wuxi, Jiangsu 214122, China

    1 shared publication

Latest Publications

  • Open Access

    Long noncoding RNA AC007637.1 inhibits tumorigenesis by regulating the Trim25/PCNA axis in colorectal cancer

    by Xue Wang, Jiuming Li, Chu Hao, Kaisa Cui, Lu Tian, Jing Zhao, Chaoqun Li, Yuyang Feng, Surui Yao, Bojian Fei, et al.


  • Open Access

    FK228 reshapes tumor microenvironment to enhance anti-PD-L1 efficacy

    by Liang Gong, Lu Tian, He Li, Kexuan Zhou, Haocheng He, Shuai Xiao, Yizhun Zhu, Zhicheng Gong, Kaisa Cui, Youming Zhang

    The lack of a favorable tumor immune microenvironment (TIME) results in limited response rates to immune checkpoint blockade (ICB) across human solid tumors, necessitating the development of novel combination strategies. In this study, we repurposed FK228, an US FDA-approved histone deacetylase inhibitor that is used clinically in non-solid tumor treatment, as a novel ICB sensitizer in solid tumors and revealed the diverse regulatory functions of FK228 in the TIME. FK228 serves as a novel necroptosis inducer in cancer cells by triggering endoplasmic reticulum stress. This in turn enhances the immunogenicity of cancer cells and increases the infiltration of tumor-killing immunocytes, including CD8+ T and natural killer cells, particularly activating tumor-infiltrated CD8+ T cells. Meanwhile, FK228 treatment shifts macrophages toward the pro-inflammatory phenotype. Moreover, the combined use of FK228 and a PD-L1 inhibitor significantly delay tumor growth and extend the survival of tumor bearing mice. Overall, our findings reveal new possibilities for the clinical application of FK228 in solid tumors and underscore the critical role of histone deacetylases in maintaining the immune-unfavorable TIME.